fda compounding glp-1 enforcement news today is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified Hims Inc. - Novo Nordisk's

doi: 10.1056/NEJMoa2204233

The Elephant in the Room: Cost and Access Sticker Shock: The exorbitant cost of these medications, often exceeding $1,000 per month in the US, places them out of reach for many who could benefit

A CVS Caremark GLP-1 Management bulletin explains that CVS requires documentation of BMI and weight, plus confirmation that the patient has been counseled on diet/exercise, before approving Wegovy or Saxenda ( [43] )

The prevalence of overweight has increased dramatically in recent decades, with nearly 2 billion people who are overweight, including 650 million obese

Furthermore, leptin receptor-deficient mice, a mouse model of obesity and diabetes, and people with endogenous glucagon deficiency (pancreatectomised individuals) treated with glucagon antisense oligonucleotide have increased hepatic fat [52, 53]